Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting

Tuesday, May 17, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Results Support Avanafil Safety and Efficacy Profile through 52 Weeks of Treatment

CONTACT:

VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris

Brian Korb

Chief Financial Officer

646-378-2923

650-934-5200



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook